| Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial. | |
| | |
MedLine Citation:
|
PMID: 16286163 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: This study sought to evaluate the efficacy and safety of fasudil, an orally available rho kinase inhibitor, in patients with stable angina. BACKGROUND: Several small, non-placebo-controlled trials suggest that fasudil reduces myocardial ischemia in patients with stable or vasospastic angina. METHODS: In a multicenter, double-blind, placebo-controlled, randomized trial, the efficacy and safety of fasudil were evaluated in stable angina patients. Of the 206 patients screened, 84 patients with reproducible exercise times were randomized 1:1 to fasudil or placebo. Nitroglycerin as needed and a beta- or calcium-channel blocker were allowed. Fasudil or matching placebo was force-titrated from 20 mg three times daily to 80 mg twice daily with 20 mg twice-daily increments every two weeks. Symptom-limited exercise testing was performed after two, four, six, and eight weeks of treatment. RESULTS: At peak, exercise duration was significantly improved at all visits in both groups, although exercise duration was numerically greater in patients receiving fasudil versus those receiving placebo. Time to > or =1 mm ST-segment depression was increased with fasudil at both peak and trough compared with placebo (172.1 s vs. 44.0 s, p = 0.001, and 92.8 s vs. 26.4 s, p = 0.02, respectively). Fasudil improved Seattle Angina Questionnaire scores. No significant differences in Canadian Cardiovascular Society class, time to angina, or frequency of angina or nitroglycerin use were noted between groups. Fasudil did not affect heart rate or blood pressure, and was well tolerated. CONCLUSIONS: Fasudil up to 80 mg three times daily significantly increased the ischemic threshold of angina patients during exercise with a trend toward increased exercise duration. Further investigation of fasudil doses >80 mg three times daily is indicated. |
| | |
Authors:
|
Ralph M Vicari; Bernard Chaitman; Deborah Keefe; William B Smith; Steven G Chrysant; Melvin J Tonkon; Neville Bittar; Robert J Weiss; Hugo Morales-Ballejo; Udho Thadani; |
Related Documents
:
|
2662743 - Comparison of atenolol and nifedipine in chronic stable angina pectoris. 1284163 - Efficacy and tolerability of slow-release gallopamil in patients with stable exercise-i... 3278823 - Gemfibrozil decreases platelet reactivity in patients with hypercholesterolemia during ... |
Publication Detail:
|
Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2005-10-19 |
Journal Detail:
|
Title: Journal of the American College of Cardiology Volume: 46 ISSN: 1558-3597 ISO Abbreviation: J. Am. Coll. Cardiol. Publication Date: 2005 Nov |
Date Detail:
|
Created Date: 2005-11-15 Completed Date: 2005-12-29 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8301365 Medline TA: J Am Coll Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 1803-11 Citation Subset: AIM; IM |
Affiliation:
|
MIMA Century Research Associates, Melbourne, Florida 32901, USA. ralph.vicari@mima.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
/
analogs & derivatives*,
therapeutic use Aged Angina Pectoris / drug therapy* Double-Blind Method Female Humans Male Middle Aged |
| Chemical | |
Reg. No./Substance:
|
103745-39-7/fasudil; 84477-87-2/1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The dying stem cell hypothesis: immune modulation as a novel mechanism for progenitor cell therapy i...
Next Document: A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization t...